Abstract:Bioequivalence studies are performed to demonstrate in vivo that two pharmaceutically equivalent products (in the US) or alternative pharmaceutical products (in the EU) are comparable in their rate and extent of absorption. By definition, for highly variable drugs (HVDs), the estimated within-subject variability is >30%. HVDs often fail to meet current regulatory acceptance criteria for average bioequivalence (ABE). The determination of the bioequivalence of HVDs has been a vexing problem since the inception of the current regulations. It is of concern not only to the generic industry but also to the innovator industry. This article reviews the definition of HVDs, the present regulatory recommendations and the approaches proposed in the literature to deal with the bioequivalence problems of HVDs. The approach of scaled ABE (SABE) is proposed as the most adequate procedure to solve the problem. It is demonstrated that SABE has firm theoretical foundations. In fact, statistical tests similar to SABE are used in various fields, such as psychology and quality control. Algorithms and numerical examples are presented to calculate SABE from the data in conventional two-period and replicate-design studies. The most important feature of SABE is that a fixed sample size is adequate to demonstrate bioequivalence regardless of within-subject variability. The conditions for reaching consistent regulatory decisions with SABE are discussed. The required sample size, for a given statistical power, depends on the regulatory criteria. Sample sizes with different criteria are demonstrated and compared with those arising from a recent informal US FDA proposal. Pragmatic considerations lead to modifications of the theoretical concept of SABE. Several modifications are proposed, including reference scaling, restriction on the estimated geometric mean ratios and possibly limiting SABE to only secondary bioequivalence metrics such as the maximum concentration. Each proposal has its own merit but is also a source of new controversy. Overall, the statistical evaluation of SABE is more complex than that of ABE, which means higher regulatory burden. Standardized open software could be very useful in this regard. A small program script is presented to calculate SABE confidence limits.

Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?

Efficient model-based bioequivalence testing

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

Comparative Analyses of Bioequivalence Assessment Methods for In Vitro Permeation Test Data

Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation

Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Machine learning driven bioequivalence risk assessment at an early stage of generic drug development

Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations

Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations

An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence

Bayesian Two-Stage Adaptive Design in Bioequivalence.

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives

A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms

Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry

Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence

Determining Equivalence for Generic Locally Acting Drug Products

Predicting Bioequivalence and Developing Dissolution Bioequivalence Safe Space in vitro for Warfarin using a Physiologically-Based Pharmacokinetic Absorption Model